Recursion Pharmaceuticals Inc.
RXRX | NASDAQ
$3.97
+$0.14 (+3.66%)
At close: Sep 21, 2026, 4:00 PM ET
$3.95
-$0.02 (-0.50%)
Pre-market:
Sep 22, 2026, 6:26 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 74.68M | 58.84M | 43.88M | 39.68M | 10M | 3.41M |
Cost of Revenue | 120.95M | 45.24M | 42.59M | 48.28M | n/a | n/a |
Gross Profit | -46.27M | 13.6M | 1.29M | -8.59M | 10M | 3.41M |
Operating Income | -648.13M | -479M | -350.06M | -245.73M | -182.78M | -84.62M |
Interest Income | 22.79M | 15.76M | 19.12M | 6.25M | 73K | 336K |
Pretax Income | -644.9M | -464.79M | -332.13M | -239.48M | -186.48M | -87.01M |
Net Income | -644.76M | -463.66M | -328.07M | -239.48M | -186.48M | -87.01M |
Selling & General & Admin | 176.59M | 178.18M | 110.82M | 81.6M | 57.68M | 25.26M |
Research & Development | 425.27M | 314.42M | 241.23M | 155.7M | 135.27M | 63.32M |
Other Expenses | n/a | n/a | -699K | -162K | -178K | -549K |
Operating Expenses | 601.86M | 492.61M | 351.35M | 237.13M | 192.78M | 88.03M |
Interest Expense | 1.81M | 1.57M | 97K | 55K | 2.95M | 1.36M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 722.81M | 537.84M | 393.94M | 285.41M | 192.78M | 88.03M |
Income Tax Expense | -136K | -1.13M | -4.06M | n/a | n/a | n/a |
Shares Outstanding (Basic) | 447.45M | 274.21M | 207.85M | 175.54M | 170.27M | 165.79M |
Shares Outstanding (Diluted) | 447.45M | 274.21M | 207.85M | 175.54M | 170.27M | 165.79M |
EPS (Basic) | -1.44 | -1.69 | -1.58 | -1.36 | -1.05 | -0.52 |
EPS (Diluted) | -1.44 | -1.69 | -1.58 | -1.36 | -1.05 | -0.52 |
EBITDA | -559.38M | -426.72M | -307.63M | -227.67M | -175.12M | -81.7M |
EBIT | -643.09M | -463.22M | -332.03M | -239.42M | -183.53M | -85.65M |
Depreciation & Amortization | 83.7M | 36.49M | 24.4M | 11.76M | 8.41M | 3.94M |
Add to Watchlist
Select watchlists to add or remove RXRX